Jacksonville

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• High blood pressure4 trials
• Amyloidosis2 trials
• Chronic kidney disease1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Liver and biliary tract cancer1 trial
• Long COVID and ME/CFS1 trial
• Myasthenia gravis1 trial

Phase

• Phase 25 trials
• Phase 33 trials
• Phase 11 trial

Status

• Completed6 trials
• Recruiting4 trials
• Active, not recruiting1 trial

Lead sponsor

• Alnylam Pharmaceuticals8 trials
• Alexion Pharmaceuticals, Inc.1 trial
• BioVie Inc.1 trial
• Priovant Therapeutics, Inc.1 trial

Running trials

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  NCT06600321· Phase 1· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

  NCT06393712· Phase 2· Alnylam Pharmaceuticals· Source

• Recruiting

  ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

  NCT04561518· Alnylam Pharmaceuticals· Source

• Recruiting

  Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

  NCT04202341· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Completed

  NE3107 in Adults With Neurological Symptoms of Long COVID

  NCT06847191· Phase 2· BioVie Inc.· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

  NCT04936035· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379· Phase 3· Alnylam Pharmaceuticals· Source